{"disease":{"id":"platinum-sensitive","name":"platinum sensitive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01847274","title":"A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT02289950","title":"A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03705156","title":"Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":265,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03534453","title":"Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04091204","title":"Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT07295132","title":"RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT02978222","title":"Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":120,"lead_sponsor_name":"Marker Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03896503","title":"Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07504588","title":"Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":87,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05231122","title":"Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT07321015","title":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04034927","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04092270","title":"A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04779151","title":"Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07454018","title":"Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04734665","title":"Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT02020707","title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01611558","title":"Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04550494","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02627443","title":"Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04907968","title":"Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT07339553","title":"Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT04607954","title":"Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05002868","title":"Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Rhizen Pharmaceuticals SA","has_results":false},{"nct_id":"NCT05353439","title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04457089","title":"Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Marc Goodman","has_results":false},{"nct_id":"NCT04861181","title":"NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03691376","title":"Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}